Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $9.99
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 13, 26 |
| TD Cowen |
| maintain |
| Hold |
| Hold |
| Sep 4, 26 | BTIG | maintain | Sell | Sell |
| Aug 7, 26 | TD Cowen | downgrade | Buy | Hold |
| Mar 12, 26 | BTIG | maintain | Sell | Sell |
| Jan 8, 26 | TD Cowen | maintain | Buy | Buy |
| Aug 25, 25 | BTIG | maintain | Sell | Sell |
| Sep 20, 24 | TD Cowen | maintain | Buy | Buy |
| Aug 23, 24 | BTIG | maintain | Sell | Sell |
| Jul 9, 24 | Goldman Sachs | maintain | Sell | Sell |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 47.35 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 4.47 | Oscillator | Buy |
| Williams %R (14) | -93.63 | Oscillator | Buy |
| MACD (12, 26, 9) | 0.16 (Hist -0.40) | Oscillator | Sell |
| Average Directional Index (14) | 48.88 (+DI 27.9 / -DI 14.9) | Trend | Strong Buy |
| EMA 20 | 10.59 | MA | Strong Sell |
| SMA 20 | 11.50 | MA | Strong Sell |
| EMA 50 | 9.77 | MA | Buy |
| SMA 50 | 9.07 | MA | Strong Buy |
| SMA 200 | 8.53 | MA | Strong Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 16, 26 | Coen Steven P. | officer: See remarks | M-Exempt | 312 | — |
| Oct 16, 26 | Coen Steven P. | officer: See remarks | M-Exempt | 1,174 | — |
| Oct 19, 26 | Coen Steven P. | officer: See remarks | S-Sale | 766 @ $10.14 | $7.77K |
| Oct 16, 26 | Coen Steven P. | officer: See remarks | M-Exempt | 1,174 | — |
| Oct 16, 26 | Coen Steven P. | officer: See remarks | M-Exempt | 312 | — |
| Oct 16, 26 | Canton Barry | 10 percent owner | M-Exempt | 10,619 | — |
| Oct 16, 26 | Canton Barry | 10 percent owner | M-Exempt | 29,279 | — |
| Oct 19, 26 | Canton Barry | 10 percent owner | S-Sale | 22,369 @ $10.14 | $226.9K |
FY2025 · 10-K disclosure
Stock news · updated daily
Hugging Face released a new AI model that allows users to "chat with DNA." Carbon-X can analyze and generate DNA and allows researchers to ask questions in plain language.
Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in multiple cancers HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational targeted radiotherapeutic. The Ovarian Cancer Research Alliance sponsored the symposium, held October 16–18, 2026, in Philadelphia.
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
Ginkgo Bioworks Inc. (NYSE:DNA) is strengthening national biotechnology infrastructure by granting remote laboratory access through the National Science Foundation's X-Labs program and integrating high-speed cellular imaging tools into its Boston facility.
/PRNewswire/ -- Araceli Biosciences und Ginkgo Bioworks (NYSE: DNA) gaben heute die Integration des Endeavor-High-Content-Imaging-Geräts von Araceli in
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs program. Ginkgo's support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C. NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engin.
/PRNewswire/ -- Araceli Biosciences y Ginkgo Bioworks (NYSE: DNA) han dado a conocer hoy la integración del instrumento de imágenes de alto contenido Endeavor
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -0.90 | -0.75 | Beat 16.2% | $20.16M |
| May 7, 2026 | -1.21 | -1.39 | Miss -14.8% | $19.47M |
| Feb 26, 2026 | -1.80 | -1.42 | Beat 21.1% | $33.00M |
| Nov 6, 2025 | -1.24 | -1.45 | Miss -16.9% | $38.84M |
| Aug 7, 2025 | -1.44 | -1.10 | Beat 23.6% | $49.60M |
| May 6, 2025 | -1.23 | -1.68 | Miss -36.6% | $48.32M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 21, 2026 | 2026-10-21 16:07:04 | View |
| 4 | Oct 21, 2026 | 2026-10-21 16:06:40 | View |
| 4 | Oct 21, 2026 | 2026-10-21 16:06:06 | View |
| 4 | Oct 21, 2026 | 2026-10-21 16:05:34 | View |
| 4 | Oct 7, 2026 | 2026-10-07 17:00:30 | View |
| 4 | Sep 16, 2026 | 2026-09-16 16:06:20 | View |
| 4 | Aug 25, 2026 | 2026-08-25 17:01:16 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 16:09:48 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 16:06:24 | View |
| 4 | Jul 30, 2026 | 2026-07-30 16:28:38 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | DNA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -2.0x | -2.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -2.6x | EPS est. -3.91 | Elevated |
| Price / Book | 1.5x | 2.7x | Discount |
| Price / Sales | 6.0x | 11.8x | Discount |
| EV / EBITDA | -4.1x | -2.6x | Elevated |
| Return on equity | -60.2% | — | Weak |
| Gross margin | 80.1% | 71.8% | In line |
| Debt / Equity | 0.96 | 0.40 | Moderate |
| Piotroski / Altman Z | 2/9 | Z -8.73 | Distress |
Discounted cash flow model